文献速递精神分裂症与精神病性障碍

精神分裂症胆碱能系统:系统综述与荟萃分析

Cholinergic system in schizophrenia: A systematic review and meta-analysis.
PubMed 文献 · Mol Psychiatry · 2025-05-20

该系统综述与荟萃分析检索Embase和Medline,共纳入61项研究(8项在体神经影像和53项尸检),比较精神分裂症/分裂情感障碍患者与对照人群。约74%的研究报告胆碱能系统显著改变,多为毒蕈碱或烟碱受体水平降低;3项荟萃分析显示纹状体、海马和前扣带皮层M1/M4毒蕈碱受体降低。

要点

  • 精神分裂症患者中枢毒蕈碱和烟碱受体水平广泛降低。
  • 荟萃分析示纹状体、海马、前扣带皮层M1/M4受体中等至大效应降低。
  • 部分神经影像研究提示受体改变与临床症状严重度及认知功能障碍相关。

核心结论

  • 精神分裂症/分裂情感障碍患者中枢胆碱能系统存在广泛的毒蕈碱和烟碱受体水平降低,神经影像与尸检研究结果一致。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase和Medline,纳入比较精神分裂症/分裂情感障碍患者与对照人群的横断面病例对照研究,遵循PRISMA 2020指南(PROSPERO: CRD42023402126),使用NIH/NHLBI病例对照研究质量评估工具评价偏倚风险。
  • 共筛选3259项研究,61项符合纳入标准,包括8项在体神经影像研究和53项尸检研究。

主要发现

  • 约74%的纳入研究报告了显著改变,最常见为精神分裂症中毒蕈碱或烟碱受体水平降低。
  • 荟萃分析显示纹状体M1/M4毒蕈碱受体降低(g = -0.809,k = 3,n = 108)。
  • 荟萃分析显示海马M1/M4毒蕈碱受体降低(g = -0.872,k = 3,n = 84)。
  • 荟萃分析显示前扣带皮层M1/M4毒蕈碱受体降低(g = -0.438,k = 4,n = 295)。
  • 6项神经影像研究报告与临床症状严重度指标的关联,4项研究与认知功能障碍的关联。

临床怎么用

  • 毒蕈碱和烟碱受体水平降低可作为精神分裂症中枢胆碱能异常的参考证据,尤其M1/M4受体在纹状体、海马和前扣带皮层的降低。
  • 部分神经影像研究提示胆碱能受体改变与临床症状严重度和认知功能障碍相关,但关联证据尚有限。

局限性

  • 原文未系统报告纳入研究的具体局限性,仅指出文中讨论了该领域的局限性与未来方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Studies have shown widespread alterations in different components of the cholinergic system in schizophrenia, but to date the evidence has not been systematically reviewed and summarized. Here, we systematically review imaging and post-mortem studies on the central cholinergic system in schizophrenia/schizoaffective disorder. SUBJECTS/METHODS: Searches were performed in Embase and Medline. Study designs included cross-sectional case control studies comparing individuals with schizophrenia/schizoaffective disorder to control population. Risk of bias was assessed with the NIH/NHLBI tool for Quality Assessment of Case-Control Studies. The current study followed the PRISMA 2020 guidelines (PROSPERO: CRD42023402126). RESULTS: A total of 3259 studies were screened and 61 met eligibility criteria for the systematic review, including 8 in vivo neuroimaging and 53 post-mortem studies. About 74% of these studies described significant alterations, most often reductions in either muscarinic or nicotinic receptor levels in schizophrenia. We also conducted 3 meta-analyses showing reductions in M1/M4 muscarinic receptors in the striatum (g = -0.809, k = 3, n = 108), hippocampus (g = -0.872, k = 3, n = 84), and fronto-cingulate cortex (g = -0.438, k = 4, n = 295). Six neuroimaging studies reported associations with clinical symptom severity measures, and four investigations with cognitive dysfunction. CONCLUSIONS: Our review demonstrates a widespread decrease in muscarinic and nicotinic receptor levels in schizophrenia, evident in both neuroimaging and post-mortem studies. Our meta-analyses show large to moderate effects for the reductions in M1/M4 muscarinic receptors in the striatum, hippocampus, and fronto-cingulate cortex. Limitations and future directions for the field are discussed.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Saint-Georges Z, MacDonald J, Al-Khalili R, et al. Cholinergic system in schizophrenia: A systematic review and meta-analysis. Mol Psychiatry. 2025. PMID: 40394282. doi:10.1038/s41380-025-03023-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。